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Abstract
Recent studies have described that the Notch signaling pathway is activated in a wide range of renal diseases. Angiotensin II
(AngII) plays a key role in the progression of kidney diseases. AngII contributes to renal fibrosis by upregulation of
profibrotic factors, induction of epithelial mesenchymal transition and accumulation of extracellular matrix proteins. In
cultured human tubular epithelial cells the Notch activation by transforming growth factor-b1 (TGF-b1) has been involved in
epithelial mesenchymal transition. AngII mimics many profibrotic actions of TGF-b1. For these reasons, our aim was to
investigate whether AngII could regulate the Notch/Jagged system in the kidney, and its potential role in AngII-induced
responses. In cultured human tubular epithelial cells, TGF-b1, but not AngII, increased the Notch pathway-related gene
expression, Jagged-1 synthesis, and caused nuclear translocation of the activated Notch. In podocytes and renal fibroblasts,
AngII did not modulate the Notch pathway. In tubular epithelial cells, pharmacological Notch inhibition did not modify
AngII-induced changes in epithelial mesenchymal markers, profibrotic factors and extracellular matrix proteins. Systemic
infusion of AngII into rats for 2 weeks caused tubulointerstitial fibrosis, but did not upregulate renal expression of activated
Notch-1 or Jagged-1, as observed in spontaneously hypertensive rats. Moreover, the Notch/Jagged system was not
modulated by AngII type I receptor blockade in the model of unilateral ureteral obstruction in mice. These data clearly
indicate that AngII does not regulate the Notch/Jagged signaling system in the kidney, in vivo and in vitro. Our findings
showing that the Notch pathway is not involved in AngII-induced fibrosis could provide important information to
understand the complex role of Notch system in the regulation of renal regeneration vs damage progression.
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Introduction
The Notch pathway is an evolutionarily conserved mechanism
involved in the formation of complex structures, such as the kidney
[1–3], that influences differentiation, proliferation, and apoptotic
events at all stages of the development [4–6]. The membrane-
bound ligands Delta-like-1/3/4 or Jagged-1/2 can bind to the
single-pass transmembrane Notch receptors (Notch1/2/3/4) [7,8].
On activation, the Notch intracellular domain (NICD) is cleaved
by c-secretases and translocates into the nucleus to interact with
the transcriptional regulator recombination signal-binding pro-
tein-1 for JKappa (RBP-Jk) and then activate downstream
transcription factors, such as hairy-and-enhancer of split 1
(HES-1) and HES-related repressor proteins (Hey), which may
mediate the effects on the cell fate [9,10].
The Notch pathway participates in physiological and patholog-
ical processes, including cancer [11], and regeneration of the
vasculature [12,13]. Regarding the kidney, Notch expression is
virtually absent in the glomeruli of healthy adult kidneys, while
Notch activation is observed in renal progenitors and podocytes of
patients with glomerular disorders [14]. Notch ligands and its
receptors are expressed in a wide range of renal diseases.
Podocyte-specific Notch expression is correlated with albuminuria
and glomeruloesclerosis, while expression of cleaved Notch-1 in
tubules is associated with tubulointerstitial fibrosis [15]. In
transgenic mice, specific Notch activation in podocytes causes
chronic glomerular injury and albuminuria [16,17]. In experi-
mental models of tubulointerstitial damage, activation of Notch is
found in tubular epithelial and interstitial cells [5,18,19]. However,
the beneficial effect of Notch modulation in renal disease
progression is still controversial [14,20,21].
TGF-b1 is a key profibrotic cytokine that contributes to
tubulointerstitial damage and renal fibrosis [22–24]. In tubular
epithelial cells, TGF-b1 activates the Notch signaling system and
stimulates the expression of the Notch ligands Jagged-1, Jagged-2,
as well as the receptors Notch-1 and Notch-4, while Notch-2
expression is not affected [18,25]. In these cells TGF-b1 induces
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epithelial-mesenchymal transition (EMT) [26]. TGF-b1-induced
Jagged-1 overexpression occurs earlier than changes in EMT-
associated genes, and blockade of Notch activation markedly
diminishes TGF-b1-mediated EMT [27]. Based on these obser-
vations, several authors have suggested that the Notch pathway
could regulate renal EMT and fibrosis.
Angiotensin II (AngII) plays a key role in the progression of
chronic kidney damage, contributing to renal fibrosis. Many in vitro
and experimental studies have demonstrated that AngII activates
renal cells to produce profibrotic factors and extracellular matrix
proteins (ECM) [28,29]. The interrelation between AngII and
TGF-b1 is well established. AngII and TGF-b1 share many,
profibrotic mediators and intracellular signaling systems [30,31].
In particular, in tubular epithelial cells both AngII and TGF-b1
can induce EMT [23,24,32], and TGF-b1 is known to activate the
Notch pathway [18,25]. For these reasons, our aim was to evaluate
the contribution of the Notch/Jagged system to AngII-induced
renal responses in this paper. We have identified a signaling
mechanism, the Notch pathway, not shared by AngII and TGF-
b1, and not involved in AngII-induced fibrosis. Our results may
have therapeutic relevance for understanding the complex relation
between renal disease progression and regeneration.
Results
AngII did not increase Jagged-1 expression in cultured
tubular epithelial cells
In cultured human tubular epithelial HK-2 cells previous studies
have shown that TGF-b1, at doses between 5 and 50 ng/mL,
actives Notch pathway and induces EMT changes [27]. Stimu-
lation of HK-2 cells with 1027 mol/L AngII did not modify
protein levels of the Notch ligand Jagged-1, at any time point
studied, while TGF-b1 significantly increased Jagged-1 synthesis,
starting at 18 hours and remaining elevated up to 48 hours
(ure 1A and B). Moreover, incubation with AngII (dose range
1026 mol/L to 10211 mol/L) showed no changes in Jagged-1
protein levels (figure 1C). Gene expression analysis of the Notch
components showed that only stimulation with TGF-b1, but not
AngII, for 24 hours increased Jagged-1 and its receptor Notch-1.
In contrast, neither TGF-b1 nor AngII modified Delta-1 and
Notch-3 gene levels (figure 1D). By confocal microscopy, activated
Notch intracellular domain (NICD) was only detected in the nuclei
of TGF-b1-treated cells, while in control or AngII-treated cells
there was no NICD immunostaining (figure 1E). These data
clearly demonstrated that in tubular epithelial cells TGF-b1, but
not AngII, increased the Notch pathway-related gene expression,
and activated Notch, determined by Jagged-1 production and
NICD nuclear translocation, where it may activate gene
transcription, as described [6,33].
Activation of the Notch pathway was not involved in
AngII-induced EMT in cultured tubular epithelial cells
In tubular epithelial cells AngII, at the dose of 1027 mol/L,
induces EMT changes and upregulation of profibrotic factors and
ECM [23,24,32,34,35]. To evaluate the role of the Notch pathway
in AngII-induced profibrotic responses cells were treated with the
c-secretase inhibitor, DAPT, which inhibits the signaling from all
Notch receptor types [6]. Preincubation of HK-2 cells for 1 hour
with DAPT inhibited TGF-b1-induced EMT phenotypic changes,
including induction of the mesenchymal marker Vimentin and
downregulation of the adhesion-related molecule Cytokeratin
(figure 2), as described [27]. By contrast, DAPT had no effect on
any AngII-induced EMT changes (figure 2). Interestingly, Notch
blockade did not modify TGF-b1 or AngII-induced changes in
other profibrotic factors, including connective tissue growth factor
(CTGF), Matrix metallopeptidase-9 (MMP-9) and Plasminogen
activator inhibitor-1 (PAI-1) mRNA upregulation (figure 2D).
We have further explored the direct role of Jagged-1 in EMT.
Incubation of HK-2 cells with Jagged-1 recombinant protein for
48 hours induced phenotypic conversion from epithelial to
fibroblast-like morphology (data not shown) and changes in
EMT markers (figure 3A). DAPT also diminished TGF-b1-
induced upregulation of Notch genes (figure 3B) and Jagged-1
production (figure 3C). All these data supporting the hypothesis
that TGF-b1 via Notch pathway activation could regulate EMT in
tubular epithelial cells.
AngII did not increase Jagged-1 expression in cultured
podocytes and renal fibroblasts
In human podocytes, TGF-b1, but not AngII, upregulated
Jagged-1 mRNA (figure 4A) and protein levels (figure 4B).
Blockade of Notch activation by DAPT significantly diminished
Jagged-1 upregulation by TGF-b1. In murine renal fibroblasts,
incubation with TGF-b1, but not AngII, increased Jagged-1
synthesis at 48 hours (figure 4B).
AngII increased TGF-b1 production in renal cells
Previous studies have demonstrated that AngII increased TGF-
b1 gene expression and production of active protein [28–32].
Next, the potential role of endogenous TGF-b1 production in the
activation of Notch pathway was evaluated. After 48 hours of
incubation with 1027 mol/L AngII a significant increase in TGF-
b1 production was found in the conditioned media of the different
cell types evaluated in the present study (HK-2, TFBs and
podocytes) (Figure 5A), in the same experiments that AngII did not
active the Notch pathway. The amount of active TGF-b1 detected
in supernatants was around 200 pg/mL. Therefore, we evaluated
whether low doses of TGF-b1 could activate the Notch pathway in
renal cells. In HK-2 cells, stimulation with TGF-b1 at low doses
(2 ng/mL to 0.5 ng/mL) did not increase Jagged-1 production,
while only doses higher than 5 ng/mL activated this pathway
(figure 5B), as previously described [27]. These data suggest that
although AngII increased active TGF-b1 protein levels, this
endogenous TGF-b1 production is not enough to activate the
Notch pathway in renal cells.
The Notch/Jagged signaling system was not activated in
the kidney of AngII-infused rats or hypertensive rats
To investigate the in vivo effect of AngII in the Notch pathway
activation in the kidney, the model of systemic infusion of AngII
into rats was used. Renal levels of Jagged-1 were not upregulated
in response to AngII infusion for 2 weeks compare to saline-
infused ones, used as controls (figure 6A and B). By immunohis-
tochemistry, we have confirmed that renal Jagged-1 expression
was not changed in response to AngII, at any time point evaluated,
up to 2 weeks (figure 6C and D). Notch activation can also be
detected by evaluation of NICD levels. In AngII or saline-infused
groups NICD immunostaining was similar (figure 6C and D). The
onset of renal fibrosis in this model is well characterized.
Upregulation of profibrotic genes, including TGF-b1, CTGF
and PAI-1, were observed at 3 days. Renal protein levels of CTGF
were increased at 3 days, Fibronectin deposition was found 1 week
later [36], while TGF-b1 protein levels were not elevated until
2 weeks [32], as we have confirmed here (figure 6E). At 2 weeks
sustained overexpression of profibrotic factors and tubulointerstit-
ial fibrosis were observed (data not shown), as described [32,34].
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We further evaluated the role of Notch pathway in hyperten-
sion-induced renal damage using the model of spontaneously
hypertensive rats (SHR). At 16 weeks of age, SHR rats presented
elevated blood pressure, increased proteinuria and urinary
albumin (Table 1), TGF-b1 overproduction (figure 6E) and
elevated collagen deposition (data not shown), compare to control
WKY of the same age. In SHR, renal Notch pathway was not
activated, shown similar levels that normotensive WKY rats
Figure 1. TGF-b1, but not AngII, increased Jagged-1 synthesis in cultured human tubular epithelial cells. Cultured human tubular
epithelial cells (HK-2) were treated with 1027 mol/L AngII or 10 ng/mL TGF-b1 for increasing times. A. Results of total protein expression were
obtained from densitometric analysis and expressed as ratio protein/GAPDH as n-fold over control as mean 6 SEM of 3 independent experiments.
*p,0.05 vs control. Figure B shows a representative Western blot experiment. C. Dose-response of AngII. HK-2 cells were stimulated with AngII
(1026 to 10211 mol/L) for 48 hours and Jagged-1 protein levels were determined by Western blot. Figure shows a representative experiment of 3
done. D. TGF-b1, but not AngII, upregulated Notch-related genes in tubular epithelial cells. Gene expression levels of jagged-1, delta-1
and notch1/3 were determined by Real Time PCR. Data are expressed as mean6 SEM of 5 experiments. *p,0.05 vs control. E. Nuclear localization of
activated Notch-1 (NICD) is only observed in TGF-b1 treated cells for 48 hours (green staining), while in control and AngII-treated cells there is no
positive NICD staining. Nuclei are in blue (DAPI staining). Figure shows a representative experiment of 2 done by confocal microscopy. Magnification
200x.
doi:10.1371/journal.pone.0040490.g001
Figure 2. Blockade of the Notch pathway inhibited TGF-b1-, but not AngII- induced EMT changes in cultured tubular epithelial cells.
HK-2 cells were pretreated with the gamma-secretase inhibitor, DAPT (361028 mol/L) for 1 hour and then stimulated with 1027 mol/L AngII or
10 ng/mL of TGF-b1 for 24 or 48 hours (gene and protein studies, respectively). Figure A shows a representative Western blot experiment B. Results
of total protein expression were expressed as mean 6 SEM of 3 independent experiments. Figure C shows gene expression levels, determined by
Real Time PCR, were shown as mean 6 SEM of 5 experiments. *p,0.05 vs control, #p,0.05 vs TGF-b1.
doi:10.1371/journal.pone.0040490.g002
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(figure 6), as described in hypertensive patients with renal injury
[15].
An additional control of the experiment was to evaluate whether
renal Notch is activated in a rat model of diabetic nephropathy
induced by streptozotocin injection (STZ). Previous studies have
demonstrated activation of renal Notch in human and experi-
mental diabetic nephropathy [16,37]. At 6 weeks after induction
of diabetic nephropathy, rats presented increased proteinuira and
Figure 3. Jagged-1 induced EMT changes in cultured tubular epithelial cells. A. HK-2 cells were treated with 50 ng/mL Jagged-1 for
48 hours. Left panel: total protein levels as mean 6 SEM of 3 independent experiments. *p,0.05 vs control; #p,0.05 vs Jagged-1. Right panel:
representative Western blot experiment. Blockade of the Notch pathway inhibited TGF-b1-induced upregulation of Notch components.
Cells were pretreated for 1 hour with 361028 mol/L DAPT and then incubated with 10 ng/mL TGF-b1 or 1027 mol/L AngII for 24 or 48 hours (gene
and protein studies, respectively). B. Gene expression levels are expressed as mean6 SEM of 5 experiments. Figure C shows a representative western
blot of Jagged-1 and data as of mean 6 SEM of 3 independent experiments. *p,0.05 vs control; #p,0.05 vs TGF- b1.
doi:10.1371/journal.pone.0040490.g003
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albuminuria (Table 1), elevated renal TGF-b1 protein levels
(figure 6E) and fibrosis (not shown). In the immunohistochemistry
experiments done in parallel with the other models, the renal
samples of the diabetic rats showed a clear up-regulation of
Jagged-1 and NICD levels, mainly in tubulointerstitial and
glomerular cells (figure 6).
Blockade of AngII receptors did not regulate Notch/
Jagged signaling system in the model of unilateral
ureteral obstruction in mice
Several groups have shown activation of Notch/Jagged in
experimental models of renal damage. Interestingly, microarray
analysis discloses that Jagged-1 is one of the most highly expressed
genes in the experimental model of unilateral ureteral obstruction
(UUO) [5,18,19]. Previous studies have demonstrated that AngII
plays a key role in the pathogenesis of UUO, and pharmacological
blockade of AngII (by ACE inhibitors or AT1 receptor antago-
nists) ameliorates disease progression [38,39]. However, there are
no studies evaluating whether AngII blockade modulates the
Notch pathway in experimental renal diseases. Thus, in UUO
model, we have observed that treatment with an AT1 antagonist
(losartan, 10 mg/kg/day), ameliorated disease progression, in-
cluding inhibition of inflammatory cell infiltration and downreg-
ulation of MCP-1 gene overexpression (figure S1), and diminution
of renal fibrosis (not shown) and TGF-b1 overproduction
(figure S1), as previously described [38,39]. Jagged-1 protein levels
were markedly increased in obstructed kidneys compare to
contralateral ones, as described [5,18,19]. In losartan-treated
mice, obstructed Jagged-1 protein levels were similar than in
untreated obstructed ones (figure 7). This data further supports the
notion that AngII regulates renal fibrosis independently of Notch
pathway.
Discussion
The main finding of this paper is that AngII does not modulate
the Notch pathway in the kidney. In in vivo studies, we have found
that systemic infusion of AngII into rats for 2 weeks, at a dose that
caused tubulointerstitial damage and fibrosis, did not upregulate
renal expression of activated Notch or Jagged-1, suggesting that
the Notch/Jagged pathway is not involved in AngII-induced renal
damage. In spontaneously hypertensive rats, studied at the time
that presented albuminuria and interstitial fibrosis, renal expres-
sion of activated Notch or Jagged-1 was similar to normotensive
healthy WKY rats of the same age. In a wide range of kidney
diseases, renal activation of the Notch components has been
described. However, these authors have observed that in patients
with hypertensive nephrosclerosis renal the Notch/Jagged-1
system was not upregulated [15]. Blockade of AngII, by ACE
inhibitors or receptor blockers, is one the current clinical therapies
that have proven to ameliorate renal disease progression [31]. In
the experimental model of UUO, we have found that AT1
antagonist treatment ameliorated renal inflammation and fibrosis,
Figure 4. TGF-b1, but not AngII, increased Jagged-1 expression in human podocytes and murine renal fibroblasts. Cells were treated
with 1027 mol/L AngII or 10 ng/mL TGF-b1 for 24 or 48 hours (gene and protein studies, respectively). In some points cells were pretreated with the
gamma-secretase inhibitor, 361028 mol/L DAPT, for 1 hour. A. In human podocytes, gene expression levels of Notch components are expressed as
mean 6 SEM of 5 experiments. *p,0.05 vs control, #p,0.05 vs TGF- b1. B. Representative Western blot of Jagged-1 levels in podocytes and
fibroblasts of 3 independent experiments.
doi:10.1371/journal.pone.0040490.g004
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by local inhibition of chemokines and profibrotic factors, including
TGF-b1, as described [38], but did not diminish renal Jagged-1
expression. Our in vitro studies clearly demonstrated that although
TGF-b1 activated the Notch pathway in renal cells [5,18,27],
AngII did not regulate this system. In cultured human tubular
epithelial cells, we have found that AngII did not up-regulate
Notch related genes, or increased Jagged-1 protein levels. Similar
results were observed in podocytes and renal fibroblasts. These
data clearly indicates that the Notch/Jagged signaling system is
not involved in renal damage associated to AngII and hyperten-
sion.
Many works have shown that the Notch/Jagged signaling is
essential for epithelial function and appears to contribute to EMT
in embryogenesis and cancer [40,41]. In cultured tubular
epithelial cells, suppression of the Notch pathway by pharmaco-
logical inhibition of c-secretase markedly inhibited phenotypic
EMT changes induced by TGF-b1 [25,27]. In these cells TGF-b1
and AngII induce EMT by common mechanisms, including the
Smad pathway and MAPK cascade [32,34]. Data presented here
demonstrated that c-secretase inhibition did not modulate AngII-
induced EMT, illustrating a different mechanism of action
between AngII and TGF-b1. Interestingly, in these cells the
Notch-1 ligand Jagged-1 induced a transition to a fibroblast-like
phenotype and changes in EMT markers, such as loss of epithelial
proteins and induction of mesenchymal markers, supporting the
importance of Notch/Jagged-1 activation in EMT regulation.
However, the contribution of EMT to renal fibrogenesis is a
matter of intense debate [24,41–44]. In this sense, in a transgenic
mice model, the specific Notch activation in tubular and interstitial
cells induced renal damage, characterized by increased cell
proliferation of both cell types and fibrosis, but changes in EMT
markers were not detected [20].
The relation between AngII and TGF-b1 in fibrosis is well
known [28–32]. Many studies have demonstrated that TGF-b1
acts as a downstream mediator of AngII-induced renal fibrosis and
both factors share several intracellular mechanisms involved in the
regulation of ECM accumulation [28,29]. In tubular epithelial
cells, we have demonstrated that although AngII increased active
TGF-b1 levels, this endogenous TGF-b1 production is not enough
to activate the Notch pathway. This observation support our in vivo
findings in the models of AngII and hypertension-induced renal
damage, both characterized by TGF-b1 overexpression and
fibrosis in the absence of Notch pathway activation, as well as
by the data in the model of UUO showing the lack of effect on
renal Jagged-1 levels, but downregulation of TGF-b1 and renal
damage, in response to AT1 antagonism. Interestingly, in a
previous study the Notch blockade did not inhibit TGF-b1-
induced upregulation of some profibrotic genes, such as CTGF,
thrombospondin, MMP-9 [27] and, as described here, PAI-1. We
have found that these genes are also upregulated by AngII
independently of Notch activation. Importantly, CTGF has been
described as a key downstream profibrotic mediator of AngII and
TGF-b1 in several cells types, including renal cells [28]. PAI-1 has
been involved in AngII-induced vascular fibrosis, independently of
TGF-b [45,46]. These data indicated that several profibrotic-
related events induced by TGF-b1 and AngII are independent of
the Notch pathway activation.
Podocyte-specific Notch activation severely injures the glomer-
ular filtration barrier in the kidney. Inhibition of the Notch
pathway by podocyte-specific genetic ablation of the Notch
coactivator RBP-Jk or pharmacological blockade of c-secretase
reversed glomerular damage and re-established the filtration
barrier [47]. Transgenic TGF-b1 overexpression cause podocyte
injury, proteinuria and progressive glomerulosclerosis [48].
Moreover, Notch inhibition modulate TGF-b-mediated p53-
dependent podocyte apoptosis [16]. In cultured human podocytes,
TGF-b1, VEGF and high glucose activate Notch pahway and
induce podocyte apoptosis [16,49]. However, in these cells AngII
did not induce apoptosis [50], and did not increase Jagged-1
production. In a rat model of diabetic nephropathy pharmaco-
logical inhibition of the Notch signaling ameliorated proteinuria
[49], showing that podocyte-specific Notch inhibition could be a
good therapeutic option for proteinuric diseases, characterized by
podocyte loss by apoptosis.
Divergent Notch functionality has been described depending on
cell type. In the vasculature Notch-3 regulates vascular tone and
cell growth/apoptosis [51,52]. In these cells AngII inhibited
Notch-3 [51], while in tubular epithelial cells, neither TGF-b1 nor
AngII modulate Notch-3. In the kidney, Notch-3 upregulation was
only observed in renal progenitors in human glomeruloesclerosis
[14], supporting the role of Notch in renal regeneration.
Figure 5. AngII increased TGF-b1 production in renal cells. The
different cell types, human tubular epithelial cells (HK-2), murine renal
fibroblasts (TFBs) and human podocytes, were treated with 1027 mol/L
AngII for 48 hours. Then, supernatants were collected, and active TGF-
b1 was determined by ELISA. Figure A shows TGF-b1 protein levels as
mean 6 SEM of 3 independent experiments analyzed by duplicate.
*p,0.05 vs control. B. Low doses of TGF-b1 did not increase
Jagged-1 protein production in tubular epithelial cells. HK-2
cells were stimulated with TGF-b1 (10 to 0.5 ng/mL) for 48 hours and
Jagged-1 protein levels were determined by Western blot. Figure shows
a representative experiment and data as mean6 SEM of 3 experiments.
*p,0.05 vs control.
doi:10.1371/journal.pone.0040490.g005
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Understanding the fine regulation of the Notch system in kidney
injury is necessary since Notch signaling may impact kidney
regeneration in addition to injury. In adult kidneys a resident renal
cell population with progenitor activity strongly expresses mem-
bers of the Notch signaling pathway [53]. In folic acid-induced
renal injury, Notch inhibition did not modify acute renal injury
and creatinine levels (a marker of renal recovery), but ameliorated
renal lesions and fibrosis, observed at 7 days [20]. Interestingly,
Notch activation was detected only in proliferating cells. In a
model of acute tubular necrosis induced by ischemia-reperfusion,
treatment with the Notch ligand Delta-like-4 facilitated renal
recovery by increasing cell proliferation [21]. These data suggest
that the described beneficial effects of Notch inhibition could be
due to the modulation of cell proliferation. Furthermore, Notch
activation in human renal progenitors stimulates cell proliferation,
whereas its downregulation is required for differentiation toward
the podocyte lineage. Indeed, persistent Notch activation induced
podocyte death by mitotic catastrophe [14]. In mouse models of
focal segmental glomerulosclerosis, Notch inhibition reduced
podocyte loss and ameliorated proteinuria during the initial
phases of glomerular injury, but Notch inhibition in the
regenerative phases of glomerular injury reduced progenitor cell
proliferation and worsened proteinuria and glomerulosclerosis
[14].
There is a lack of effective therapy for chronic renal diseases.
The beneficial effect of Notch inhibition in experimental
proteinuric glomerular diseases, including diabetic nephropathy,
shows the importance of Notch activation in podocyte failure.
However, we describe here that the Notch pathway is not involved
in AngII-induced fibrotic events. AngII contributes to renal
damage progression, by inducing fibrosis-related events, and its
blockade retards renal disease progression in humans. Although
there are some current clinical trials using the c-secretase
inhibitors for diseases as diverse as Alzheimer’s and leukemia
[47], our experimental studies does not support the potential
beneficial effect of these drugs in AngII-mediate renal diseases.
Our results show the complexity of the regulation of the Notch
pathway in the kidney, and suggest that the involvement of this
pathway in renal disease progression could be due to regulation of
regeneration [14,21] rather than by its contribution to fibrosis.
Our findings clearly indicate that more studies are necessary to
improve the actual therapeutic approaches to limit renal damage
progression, before the use of the c-secretase inhibitors for human
diseases.
Methods
Ethics Statement
All experimental procedures were approved by the Animal Care
and Use Committee of the IIS-Fundacio´n Jimenez Diaz,
according to the guidelines for ethical care of the European
Community.
Experimental models
The model of systemic infusion of AngII was done in 3-month-
old male Normotensive Wistar-Kyoto (WKY, Criffa, Barcelona,
Spain). AngII (Biochem) dissolved in saline was infused at the dose
of 100 ng/kg/min by subcutaneous osmotic minipumps (Alza
Corp) for different time periods (from 24 hours to 2 weeks; n = 8
animals per group). A control group of saline-infused rats of the
same age was also studied (n = 8 animals). SHR male rats of
16 weeks of age were studied as control group normotensive WKY
of the same age were used (n = 8 animals per group).
Diabetic nephropathy (DN) was induced by two streptozotocin
(STZ) injections (50 mg/kg per day) or vehicle (0.01 mol/L citrate
buffer pH 4.5) in 6 week-old normotensive Wistar-Kyoto rats
which were studied after 6 weeks of diabetes (n = 10 animals per
group). Insulin (1–4 IU subcutaneous, Insulatard NPH) was
administrated weekly to prevent death from 7 days after admin-
istration of STZ, once all animals had blood glucose levels
.400 mg/dl. Systolic blood pressure was measured monthly in
conscious, restrained rats by the tail-cuff sphygmomanometer
(NARCO, Biosystems). The average of three separate measure-
ments was calculated at each time point. Albuminuria in 24 hour/
urine samples was assessed by ELISA (Celltrend, Luckenwalde,
Germany). The control group was the same as SHR rats.
The model of unilateral ureteral obstruction (UUO) was done in
male C57BL/6 mice. The model was performed under isoflurane-
induced anesthesia; the left ureter was ligated with silk (4/0) at two
locations and cut between ligatures to prevent urinary tract
infection (obstructed kidney), as described [38]. Some animals
were treated with the AT1 antagonist Losartan (MSD, Spain;
10 mg/kg per day; drinking water), starting 1 day before UUO
and continued for 5 days (n = 6 mice per group).
At the time of sacrifice, animals were anesthetized with 5 mg/kg
xylazine (Rompun, Bayer AG) and 35 mg/kg ketamine (Ketolar,
Fisher) and the kidneys perfused in situ with cold saline before
removal. A piece of the kidney (2/3) was fixed, embedded in
paraffin, and used for immunohistochemistry, and the rest was
snap-frozen in liquid nitrogen for renal cortex RNA and protein
studies. In UUO model, studies were done comparing both
kidneys (contralateral and obstructed) in each mouse. In addition,
a control group of sham-operated mice was also done, showing the
same results than contralateral kidneys (data not shown).
Figure 6. Renal Notch pathway is not upregulated in AngII-infused rats or in SHR. Infusion of AngII (100 ng/kg/min) was done in
normotensive rats from 24 hours to 2 weeks, saline infusion was used as control. Spontaneously hypertensive rats (SHR) of 16 weeks were studied,
WKY of the same age were used as control, and streptozotocin-induced diabetic rats (STZ), a known model of activated renal Notch. Renal jagged-1
protein levels were elevated only in STZ rats, but not in AngII-infused or SHR rats. In total renal extracts, Jagged-1 levels were determined
by western blot. Figure A shows a representative experiment of 2 animals per group and in B data as mean6 SEM of 8 210 rats per group. *p,0.05
vs control WKY. Jagged-1 and Notch intracellular domain (NICD) expression were evaluated by immunohistochemistry. C.
Quantification of stained area as mean 6 SEM of 8–10 animals per group. *p,0.05 vs control WKY. Figure D shows a representative picture of each
group. Original magnification 200x. Renal TGF-b1 protein levels were determined by ELISA. Figure E shows data of active TGF-b1 in total renal
extracts expressed as mean 6 SEM of 4–6 rats per group. *p,0.05 vs its corresponding control group.
doi:10.1371/journal.pone.0040490.g006
Table 1. Data of the experimental models of spontaneously
hypertensive rats (SHR) and diabetic nephropathy induced by
streptozotocin injection (STZ).
Systolic BP
(mmHg)
Protenuria
(mg/24h)
Urinary Albumin
(mg/24h)
Control 112.063.9 4.561.8 0.4460.3
SHR 143.1610.2 8.863.6 2.0060.7
STZ 121.264.8 8.663.6 2.3160.4
doi:10.1371/journal.pone.0040490.t001
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Cell cultured studies
Human renal proximal tubular epithelial cells (HK-2 cell line,
ATCC CRL-2190) were grown in RPMI 1640 medium with 10%
fetal bovine serum (FBS), 2 mmol/L glutamine, 100 U/mL
penicillin, 100 mg/mL streptomycin, 5 mg/mL Insulin Transferrin
Selenium (ITS) and 36 ng/mL hydrocortisone in 5% CO2 at
37uC. At 60–70% of confluence, cells were growth-arrested in
serum-free medium for 24 hours before the experiments.
Human podocytes are an immortalized cell line, transfected
with a temperature-sensitive SV40 gene construct and a gene
encoding the catalytic domain of human telomerase [54]. At a
permissive temperature of 33uC, the cells remain in an undiffer-
entiated proliferative state, whereas raising the temperature to
37uC results in growth arrest and differentiation to the parental
podocyte phenotype. Undifferentiated podocyte cultures were
maintained at 33uC in RPMI 1640 medium with penicillin;
streptomycin; insulin, transferrin, and selenite; and 10% FBS.
Once cells had reached 70 to 80% confluence, they were cultured
at 37uC for at least 14 days before use, when full differentiation
had taken place. For experiments, cells were cultured in serum-
free medium 24 hours before the addition of the stimuli and
throughout the experiment.
Murine renal cortical fibroblasts (TFB cell line) originally
obtained from Dr. Eric Neilson (Vanderbilt University) were
grown in RPMI 1640 with 10% FBS, 2 mM glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin in 5% CO2 at 37uC [55].
At 60–70% of confluence, cells were growth-arrested in serum-free
medium for 24 hours before the experiments.
Cells were cultured in six-well plates, serum starved for 24 hours
and treated with vehicle (PBS), recombinant human TGF-b1
(Peprotech), recombinant Ang II (Sigma) or recombinant human
Jagged-1 (R&D systems) for 24 or 48 hours in serum-free medium.
The c-secretase inhibitor IX (DAPT, Calbiochem) was added
together with TGF-b1 at 361028 mol/L DAPT for 24 hours.
DMSO, used as solvent, had no effect on cell viability and gene
expression (not shown). Cells were used for protein or RNA
studies, and the supernatants (cell-conditioned media) for TGF-b1
measurements.
Protein studies
Cells were homogenized in lysis buffer (50 mmol/L Tris/HCl;
150 mol/L NaCl; 2 mmol/L EDTA; 2 mmol/L EGTA; 0.2%
Triton X-100; 0.3% IGEPAL, 10 ml/mL protease inhibitors
cocktail; 1 ml/mL PMSF, 1 ml/mL and 10 ml/mL orthovanadate)
and then separated by SDS-polyacrylamide gel electrophoresis.
Jagged-1 and EMT markers were determined in total protein
extracts by western blot, 20 mg of proteins were loaded in each
lane. Protein content was determined by the BCA method (Pierce,
Rockford). The efficacy of protein transfer to the membranes was
assessed by Red Ponceau staining (data not shown). To evaluate
equal loading, membranes were stained with anti-GAPDH
antibody. The autoradiographs were scanned using the GS-800
Calibrated Densitometer (Quantity One, Bio-Rad). The following
primary antibodies were employed [dilution]: Jagged-1 (Santa
Cruz, [1:500]); Vimentin (R&D, [1/10000]); pan-Cytokeratin
(Sigma-Aldrich, [1/10000]); GAPDH (Chemicon International,
[1/5000]).
Paraffin-embedded kidney biopsy specimens were used for
evaluation of Jagged-1 and Notch intracellular domain (NICD)
staining. Specific biotinylated secondary antibodies were used,
followed by streptavidin–horseradish peroxidase conjugate, and
developed with diaminobenzidine. The following primary anti-
bodies were employed [dilution]: Jagged-1 (Santa Cruz, [1:100]);
NICD (Abcam, [1:300]). Briefly, 5 mm thick renal sections were
Figure 7. AT1 antagonism increased renal Jagged-1 protein levels in the model of unilateral ureteral obstructed kidneys in mice.
The figure A shows a representative experiment of Jagged-1 protein levels evaluated by western blot and in B data as mean 6 SEM of 6 animals per
group. *p,0.05 vs contralateral kidneys.
doi:10.1371/journal.pone.0040490.g007
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deparaffinized and endogenous peroxidase was blocked by 3%
H2O2 for 20 min. Then, the sections were incubated overnight at
4uC with specific primary antibodies. The specificity was checked
by omission of primary antibodies.
For immunocytochemistry experiments, cells were grown on
coverslips. After incubation, cells were fixed in paraformaldehyde
4% and permeabilized with 0.2% Triton-X100 for 10 min. After
blocking with 3% BSA, they were incubated with primary
antibodies: anti NICD (abcam, 1:300) overnight at 4uC, followed
by a AlexaFluorH 488 secondary antibody (Invitrogen) for 1 h.
Nuclei were stained with 49,6-Diamidino-2-phenyindole (DAPI).
Absence of primary antibody was used as negative control.
Samples were mounted in Mowiol 40–88 (Sigma-Aldrich) and
examined by a Leica DM-IRB confocal microscope.
For the evaluation of TGF-b1 protein levels an ELISA kit from
eBioscience was used, and TGF-b1 levels were quantified by
comparison with a standard curve. In the in vitro studies, the
conditioned media were collected to evaluate active TGF-b1 (as
described above), and data were expressed as fold-change over
untreated cells. In the different experimental models, renal TGF-
b1 protein levels were evaluated in 0.1 mg/mL of total renal
protein extracts, and data were expressed as fold-change the mean
of value of the corresponding control animal in each model.
Gene expression studies
Total RNA was isolated from cells with Trizol (Invitrogen).
cDNA was synthesized from 2 mg of total RNA primed with
random hexamer primers using the High capacity cDNA Archive
Kit (Applied). Multiplex real time PCR was performed using
Applied Biosystems expression assays (Taqman Fam fluorophore)
as follows: Jagged1: Hs01070032_m1; Notch1: Hs 00413187_m1;
Delta1: Hs01128541_m1, Notch3: Hs00194509_m1, Vimentin:
Hs00185584_m1; MMP-9: Hs00234579_m1 PAI-1:
Hs00167155_m1 and CTGF: Hs00170014_m1. Data were
normalized to 18S eukaryotic ribosomal RNA: 4210893E (Vic).
The mRNA copy numbers were calculated for each sample by the
instrument software using Ct value (‘‘arithmetic fit point analysis
for the lightcycler’’). Results were expressed in copy numbers,
calculated relative to unstimulated cells after normalization against
18S.
Statistical analysis
Results are expressed as n-fold increase over control as mean 6
SEM. Differences between groups were assessed by Mann-
Whitney test. p,0.05 was considered significant. Statistical
analysis was conducted using the SPSS statistical software (version
11.0, Chicago, IL).
Supporting Information
Figure S1 AT1 antagonist treatment ameliorates renal
damage in the model of unilateral ureteral obstruction
in mice. Animals were treated daily with the AT1 antagonist
losartan, starting 1 day before unilateral obstruction, and animals
were studied 5 days after obstruction. A. In obstructed kidneys
there is a marked inflammatory cell infiltration that was
diminished in Losartan-treated mice. The figure A shows of
CD3 lymphocytes immunostaining of a representative animal of
each group (magnification 200x). B. Losartan downregulated
proinflammatory factors. The MCP-1 gene expression was
evaluated by real time PCR. C. Losarta-n diminished renal
TGF-b1 protein levels. TGF-b1 was determined by ELISA.
Data is shown as mean 6 SEM of 6 animals per group. *p,0.05
vs contralateral kidneys. # p,0.05 vs untreated.
(TIF)
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